Drug Profile
CX 1010
Alternative Names: CX1010Latest Information Update: 23 Jul 2015
Price :
$50
*
At a glance
- Originator Unknown
- Developer Celentyx
- Class Antiepileptic drugs; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Epilepsy
Most Recent Events
- 11 Sep 2007 Phase-II clinical trials in Epilepsy in United Kingdom (unspecified route)